Lidocaine levels measured in brain tumors during surgery

NCT ID NCT04716699

Completed Knowledge-focused Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed phase 1 trial measured how much lidocaine, a common pain reliever, reaches the tumor and blood in 12 adults undergoing surgery for glioblastoma. Researchers collected blood and tumor samples at multiple times to understand the drug's levels. The goal was to gather information that might help develop future treatments for this aggressive brain cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lidocaine
What this could lead to: If successful, this study could help researchers design new treatments that use lidocaine to improve outcomes for glioblastoma patients.
What could go wrong: This is a very small, early-phase study with only 12 participants, focused on measuring drug levels rather than proving any treatment benefit. It may not lead to any new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.